Unraveling mechanistic insights into the role of microbiome in neurogenic hypertension: A comprehensive review

• Published in: Pathology, research and practice Vol. 249; p. 154740
• Main Authors: Dai, Yusang, Shen, Zheng, Khachatryan, Lusine G., Vadiyan, Diana E., Karampoor, Sajad, Mirzaei, Rasoul
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01-09-2023
• Subjects: Dysbiosis; Gut-brain axis; Inflammation; Microbial metabolites; Microbiome; Neurogenic hypertension; Probiotics; Probiotics; Microbial metabolites; Gut-brain axis; Inflammation; Neurogenic hypertension; Dysbiosis; Microbiome
• ISSN: 0344-0338; 1618-0631
• DOI: 10.1016/j.prp.2023.154740

Neurogenic hypertension, a complex and multifactorial cardiovascular disorder, is known to be influenced by various genetic, environmental, and lifestyle factors. In recent years, there has been growing interest in the role of the gut microbiome in hypertension pathogenesis. The bidirectional communication between the gut microbiota and the central nervous system, known as the microbiota-gut-brain axis, has emerged as a crucial mechanism through which the gut microbiota exerts its influence on neuroinflammation, immune responses, and blood pressure regulation. Recent studies have shown how the microbiome has a substantial impact on a variety of physiological functions, such as cardiovascular health. The increased sympathetic activity to the gut may cause microbial dysbiosis, increased permeability of the gut, and increased inflammatory reactions by altering a number of intestinal bacteria producing short-chain fatty acids (SCFAs) and the concentrations of lipopolysaccharide (LPS) in the plasma. Collectively, these microbial metabolic and structural compounds stimulate sympathetic stimulation, which may be an important stage in the onset of hypertension. The result is an upsurge in peripheral and central inflammatory response. In addition, it has recently been shown that a link between the immune system and the gut microbiota might play a significant role in hypertension. The therapeutic implications of the gut microbiome including probiotic usage, prebiotics, dietary modifications, and fecal microbiota transplantation in neurogenic hypertension have also been found. A large body of research suggests that probiotic supplementation might help reduce chronic inflammation and hypertension that have an association with dysbiosis in the gut microbiota. Overall, this review sheds light on the intricate interplay between the gut microbiome and neurogenic hypertension, providing valuable insights for both researchers and clinicians. As our knowledge of the microbiome's role in hypertension expands, novel therapeutic strategies and diagnostic biomarkers may pave the way for more effective management and prevention of this prevalent cardiovascular disorder. Exploring the potential of the microbiome in hypertension offers an exciting avenue for future research and offers opportunities for precision medicine and improved patient care.